Related Experiment Video

Updated: Jul 2, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K

Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers

Khine S Shan1, Amalia Bonano-Rios1, Nyein Wint Yee Theik2

  • 1Division of Hematology and Oncology, Memorial Health Care, Pembroke Pines, FL 33028, USA.

International Journal of Molecular Sciences
|February 24, 2024
PubMed

Insights

Dysregulated phosphatidylinositol-3-kinase (PI3K) pathway drives cancer. While PI3K inhibitors show promise, their clinical use is limited by efficacy, toxicity, and resistance, necessitating further research.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphatidylinositol-3-kinase (PI3K) pathway is crucial for cellular functions.
  • Its dysregulation is a key driver of uncontrolled cell growth and cancer development.
  • Several PI3K inhibitors have been FDA-approved, demonstrating therapeutic potential.

Purpose of the Study:

  • To review the PI3K signaling pathway and its role in carcinogenesis.
  • To discuss current and emerging PI3K pathway inhibitors.
  • To explore challenges, resistance mechanisms, and future directions for PI3K inhibitor therapy.

Main Methods:

  • Literature review of PI3K signaling.
  • Analysis of PI3K pathway alterations in cancer.
  • Summary of clinical data and preclinical studies on PI3K inhibitors.
  • Examination of resistance mechanisms and adverse effects.

Main Results:

  • PI3K pathway dysregulation is implicated in numerous cancers.
  • Approved PI3K inhibitors have shown efficacy but face limitations.
  • Resistance mechanisms and toxicities hinder widespread clinical application.

Conclusions:

  • Targeting the PI3K pathway remains a critical area in cancer therapy.
  • Overcoming resistance and managing toxicity are key challenges.
  • Novel inhibitors and combination strategies are essential for future progress.
Keywords:
AKTPI3KmTORmolecular profilingpersonalized medicinephosphatidylinositol-3-kinasetargeted therapy

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.5K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.9K